– FOUR ONGOING CLINICAL TRIALS ON THREE DRUG CANDIDATES
– UPDATE ON NEW ACTIVE AGENT SCREENING PLATFORM NEUROLEAD
Lyon, 13 February 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its year-end cash position and presents an update on the current status of its activities.
Total available funds on 31 December 2018 stood at €15.2M, compared with €15.8M on 30 September 2018, reflecting effective cost control. These figures take into account the €720k Research Tax Credit paid out in Q4 2018.
“This past year marked the launch of new studies serving to bolster and round out our portfolio of clinical drug candidates. Alongside these achievements, Theranexus has succeeded in keeping firm control of its cash consumption. The 2019 financial year promises to be full of exciting clinical breakthroughs, with Phase II results in narcolepsy treatment expected very soon, followed by Phase II results in Parkinson’s disease patients and Phase I proof of concept results for neurocognitive disorders. In addition to plentiful news regarding clinical testing, the coming year will see the deployment of Neurolead, our new high value-added active agent screening platform, designed to address unmet medical needs,” said Franck Mouthon, Chairman and CEO of Theranexus.
